InteliSwab COVID-19 Rapid Test (2 Test/Box)


Sale price$24.99

ATTENTION! Your health insurance may provide coverage for this product. Please check THIS listing and find out if your insurance will reimburse you! If you have specific insurance questions, submit a request for additional information by emailing PayerRelations@prism-medical.com

IMPORTANT! Please read the COVID-19 Test Kit Notice carefully. (The notice will open as a PDF file.) If you agree to the terms and conditions in the COVID-19 Test Kit Notice, click "I Agree" to enable the "Add to Cart" button.

I agree

Description

Meet InteliSwab, the COVID-19 rapid antigen test that makes self-testing remarkably simple. It’s so user-friendly, it can be used anytime and anywhere, and requires less than one minute of hands-on time. InteliSwab has received FDA Emergency Use Authorization* for self-testing. You do not need to ship samples to a lab or get a prescription from your healthcare provider. Use requires just 3 key steps: Swab, Swirl and See your result in 30 minutes. There is no assembly required. InteliSwab makes testing so easy, you’ll know you did it right.

  • Detects active COVID-19 infection for both symptomatic and asymptomatic use
  • Shallow and gentle nasal swab (lower nostril)
  • 98% of untrained, unproctored users found InteliSwab™ easy to use
  • Requires less than one minute of hands-on time
  • No lab needed and no assembly required
  • Get your results in 30 minutes
  • No difficult or confusing steps
  • No dropper bottle or number of drops required
  • No batteries or instruments needed
  • Designed in Bethlehem, Pennsylvania by OraSure Technologies, Inc.
  • Suitable for ages 15 and up
  • Bilingual instructions included

*This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA; This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and, This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.


Related Products